Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Namwiwat Medical PCLBKK:NAM 39 5-Year Yield-on-Cost % is 3.85 as of Jul. 28, 2026, which is 11% above its 10-year median of 3.47. GuruFocus rates BKK:NAM with a GF Score™ of 39/100 and a GF Value™ of ฿5.97 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 323 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks better than 66.56% on this metric.
Namwiwat Medical PCL's yield on cost for the quarter that ended in Mar. 2026 was 3.85.
The historical rank and industry rank for Namwiwat Medical PCL's 5-Year Yield-on-Cost % or its related term are showing as below:
BKK:NAM'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.75 Med: 3.47 Max: 7.14
Current: 3.85
During the past 6 years, Namwiwat Medical PCL's highest Yield on Cost was 7.14. The lowest was 1.75. And the median was 3.47.
BKK:NAM's 5-Year Yield-on-Cost % is ranked better than 66.56% of 323
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs BKK:NAM: 3.85
Namwiwat Medical PCL (BKK:NAM) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Namwiwat Medical PCL 5-Year Yield-on-Cost % Related Terms
BKK:NAM vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Namwiwat Medical PCL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's 5-Year Yield-on-Cost % falls into.
Namwiwat Medical PCL 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Namwiwat Medical PCL (BKK:NAM) has a 5-Year Yield-on-Cost % of 3.85 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Namwiwat Medical PCL and its competitors. This is 11% above median its historical median of 3.47. Over the past decade, Namwiwat Medical PCL's 5-Year Yield-on-Cost % has ranged from 1.75 to 7.14. According to the industry distribution chart, Namwiwat Medical PCL ranks #108 out of 323 companies in the Medical Devices & Instruments industry, placing it in the top 33.4%.
Is Namwiwat Medical PCL's 5-Year Yield-on-Cost % too high?
Namwiwat Medical PCL's current 5-Year Yield-on-Cost % of 3.85 is 11% above median its 10-year median of 3.47. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 7.14. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.51. Namwiwat Medical PCL's value of 3.85 is 53.4% above this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #108 out of 323 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #108 out of 323 companies for 5-Year Yield-on-Cost %. This puts Namwiwat Medical PCL in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.51. Namwiwat Medical PCL's value of 3.85 is 53.4% above this benchmark. Historically, Namwiwat Medical PCL's own 5-Year Yield-on-Cost % has ranged from 1.75 to 7.14 over the past decade. While the company's 10-year median is 3.47 vs. the industry median of 2.51, Namwiwat Medical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.51, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current 5-Year Yield-on-Cost % of 3.85 is 53.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current 5-Year Yield-on-Cost % is 3.85, which is 11% above median its own 10-year median of 3.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿5.97, compared to a current price of ฿3.38 — trading 43.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.85, which is 11% above median its 10-year median of 3.47 and 53.4% above the Medical Devices & Instruments industry median of 2.51. Namwiwat Medical PCL's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current 5-Year Yield-on-Cost % is 3.85 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.38 is trading 43.4% below its estimated GF Value™ of ฿5.97.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
5-Year Yield-on-Cost %: 3.85 (11% above median its 10-year median of 3.47)
GF Value™: ฿5.97 vs. price of ฿3.38 (43.4% below fair value)
Industry Position: 53.4% above the Medical Devices & Instruments median (#108 of 323)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
39GF Score
Get the complete analysis for BKK:NAM
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
